UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome

International Urogynecology Journal, 2018-07, Vol.29 (7), p.1045-1050

2018

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.952-960

2018

Volltextzugriff (PDF)

Does irritable bowel syndrome increase the risk of interstitial cystitis/bladder pain syndrome? A cohort study of long term follow-up

International Urogynecology Journal, 2021-05, Vol.32 (5), p.1307-1312

2021

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects

Journal of clinical pharmacology, 2014-05, Vol.54 (5), p.528-536

2014

Volltextzugriff (PDF)

Will cesarean section increase the risk of interstitial cystitis/painful bladder syndrome?

Neurourology and urodynamics, 2018-11, Vol.37 (8), p.2638-2644

2018

Volltextzugriff (PDF)

Predictive models for detecting patients more likely to develop acute myocardial infarctions

The Journal of supercomputing, 2022-02, Vol.78 (2), p.2043-2071

2022

Volltextzugriff (PDF)

Comparison of outpatient reimbursement for interstitial cystitis/bladder pain syndrome and rheumatoid arthritis treatment in Taiwan: A nationwide population‐based study

Lower urinary tract symptoms, 2019-04, Vol.11 (2), p.O162-O167

2019

Volltextzugriff (PDF)

Fertility and pregnancy outcomes after uterine artery occlusion with or without myomectomy

Taiwanese journal of obstetrics & gynecology, 2012-09, Vol.51 (3), p.331-335

2012

Volltextzugriff (PDF)

Mechanism of Hormone-Stimulated Lipolysis in Adipocytes: Translocation of Hormone-Sensitive Lipase to the Lipid Storage Droplet

Proceedings of the National Academy of Sciences - PNAS, 1992-09, Vol.89 (18), p.8537-8541

1992

Volltextzugriff (PDF)

ELENBECESTAT PHARMACOKINETIC DRUG-DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P605-P606

2017

Volltextzugriff (PDF)

ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P250-P251

2017

Volltextzugriff (PDF)

Somatic symptoms are sensitive in predicting interstitial cystitis/bladder pain syndrome: A nationwide cohort study

International journal of psychiatry in medicine, 2017-01, Vol.52 (1), p.48-61

2017

Volltextzugriff (PDF)

PHASE 1 INVESTIGATION INTO THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF E2027, A SELECTIVE PHOSPHODIESTERASE-9 (PDE9) INHIBITOR

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P574-P575

2017

Volltextzugriff (PDF)

A cohort study of interstitial cystitis/bladder pain syndrome and hysterectomy

International Urogynecology Journal, 2016-09, Vol.27 (9), p.1401-1407

2016

Volltextzugriff (PDF)

Somatic symptoms are sensitive in predicting interstitial cystitis/bladder pain syndrome

International journal of psychiatry in medicine, 2017-01, Vol.52 (1), p.48

2017

Volltextzugriff (PDF)

A cohort study of interstitial cystitis/bladder pain syndrome (IC/BPS) and hysterectomy in Taiwan: A nationwide population-based, propensity score–matched cohort study

Urological science, 2015-12, Vol.26 (4), p.299-300

2015

Volltextzugriff (PDF)

Control of endogenous phosphorylation of the major cAMP-dependent protein kinase substrate in adipocytes by insulin and beta-adrenergic stimulation

The Journal of biological chemistry, 1990-11, Vol.265 (31), p.18769-18775

1990

Volltextzugriff (PDF)

Pharmacokinetic (PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration (P1.5-029)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: Evidence from a nested case-control study and a retrospective cohort study

Medicine (Baltimore), 2017-05, Vol.96 (18), p.e6304-e6304

2017

Volltextzugriff (PDF)

A tandem chromatographic column method for assaying cAMP-dependent protein kinase and protein kinase C with synthetic peptide substrates

Analytical biochemistry, 1988-12, Vol.175 (2), p.552-561

1988

Volltextzugriff (PDF)

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P289-P289

2018

Volltextzugriff (PDF)

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_5), p.P289-P289

2018

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018, Vol.WCP2018, p.PO1-11-13

2018

Volltextzugriff (PDF)

O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_4), p.P251-P251

2018

Volltextzugriff (PDF)

[P1–056]: POPULATION PHARMACOKINETIC‐PHARMACODYNAMIC (PK/PD) MODELING OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS

Alzheimer's & dementia, 2017-07, Vol.13 (7S_Part_5), p.P258-P258

2017

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(69)

Publikationsform

Sprache

Englisch
(86)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(26)
Humans
(19)
Technology
(18)
Male
(15)
Female
(14)
Engineering
(11)
Physical Sciences
(11)
Adult
(9)
Biological And Medical Sciences
(9)
Engineering, Electrical & Electronic
(9)
Materials Science
(9)
Middle Aged
(9)
Computer Science
(7)
Adolescent
(6)
Animals
(6)
Chemistry
(6)
Materials Science, Multidisciplinary
(6)
Medical Sciences
(6)
Obstetrics & Gynecology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome

Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs

Does irritable bowel syndrome increase the risk of interstitial cystitis/bladder pain syndrome? A cohort study of long term follow-up

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects

Will cesarean section increase the risk of interstitial cystitis/painful bladder syndrome?

Predictive models for detecting patients more likely to develop acute myocardial infarctions

Comparison of outpatient reimbursement for interstitial cystitis/bladder pain syndrome and rheumatoid arthritis treatment in Taiwan: A nationwide population‐based study

Fertility and pregnancy outcomes after uterine artery occlusion with or without myomectomy

Mechanism of Hormone-Stimulated Lipolysis in Adipocytes: Translocation of Hormone-Sensitive Lipase to the Lipid Storage Droplet

ELENBECESTAT PHARMACOKINETIC DRUG-DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS

ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG

Somatic symptoms are sensitive in predicting interstitial cystitis/bladder pain syndrome: A nationwide cohort study

PHASE 1 INVESTIGATION INTO THE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF E2027, A SELECTIVE PHOSPHODIESTERASE-9 (PDE9) INHIBITOR

A cohort study of interstitial cystitis/bladder pain syndrome and hysterectomy

Somatic symptoms are sensitive in predicting interstitial cystitis/bladder pain syndrome

A cohort study of interstitial cystitis/bladder pain syndrome (IC/BPS) and hysterectomy in Taiwan: A nationwide population-based, propensity score–matched cohort study

Control of endogenous phosphorylation of the major cAMP-dependent protein kinase substrate in adipocytes by insulin and beta-adrenergic stimulation

Pharmacokinetic (PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration (P1.5-029)

Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: Evidence from a nested case-control study and a retrospective cohort study

A tandem chromatographic column method for assaying cAMP-dependent protein kinase and protein kinase C with synthetic peptide substrates

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES

[P1–056]: POPULATION PHARMACOKINETIC‐PHARMACODYNAMIC (PK/PD) MODELING OF E2027, A SELECTIVE PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS

Suchergebnisse filtern